CMP Pharma announced the availability of Tadliq®, an oral suspension formulation of tadalafil, for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability.

Tadliq is designed for patients who have difficulty swallowing tadalafil tablets and is expected to address inconsistencies seen with compounded products. This is the first oral suspension formulation of tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor, approved by the Food and Drug Administration.

Tadliq is supplied as a peppermint-flavored suspension containing 20mg of tadalafil per 5mL in 150mL bottles. The oral suspension can be stored at room temperature.

References

  1. CMP Pharma, Inc announces that Tadliq®, the first and only fda-approved liquid suspension of tadalafil, is now available. News release. CMP Pharma, Inc. Accessed October 24, 2022. https://www.prnewswire.com/news-releases/cmp-pharma-inc-announces-that-tadliq-the-first-and-only-fda-approved-liquid-suspension-of-tadalafil-is-now-available-301656771.html
  2. Tadliq. Package insert. CMP Pharma, Inc; 2022. Accessed October 24, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214522s000lbl.pdf